Although exogenous transforming growth factor-b (TGF-b) is known to inhibit branching morphogenesis in mouse embryonic lungs in culture, whether the principal negative function of endogenous TGF-b signaling resides in lung epithelium or mesenchyme remains unresolved. A recombinant adenovirus was constructed, containing a mutated human TGF-b type II receptor with a truncated cytoplasmic kinase domain. We examined whether this dominant-negative receptor could abolish epithelium-specific endogenous TGF-b signaling. We introduced the recombinant adenovirus into lung explants via intra-tracheal micro-injection. This resulted in over-expression of exogenous truncated TGF-b type II receptor only in airway epithelium, not in mesenchyme, as assessed by mRNA level and protein localization. Blockade of endogenous TGF-b receptor signaling in epithelial endoderm by the mutated dominant-negative TGF-b type II receptor resulted in significant (65%) stimulation of epithelial branching morphogenesis, while exogenous TGF-b no longer downregulated epithelial PCNA immunoreactivity and surfactant protein C (SP-C) expression. Additionally, the mitogenic responses to epidermal growth factor (EGF) and platelet-derived growth factor, PDGF-AA were potentiated by 33 and 31%, respectively. We conclude that epithelium-specific adenovirus-mediated over-expression of a dominant-negative TGF-b type II receptor completely and specifically abolished the antiproliferative effects of both endogenous and exogenous TGF-b. Therefore, epithelium-specific TGF-b signaling is sufficient to negatively regulate embryonic lung-branching morphogenesis in culture. We speculate that abrogation of TGF-b signaling stimulates lung morphogenesis by potentiating the inductive and permissive effects of other endogenous peptide growth factors such as EGF and PDGF-AA.
Introduction
Interactions between the mesenchyme and the epithelium are required for the development of many organs, including those of the gastrointestinal, integumental, urogenital and respiratory systems. Lung development occurs as outgrowths of primitive respiratory epithelium from the foregut endoderm, that invade the surrounding mesodermal mesenchyme to form the bronchial tree, in a geneticallypredetermined pattern of branching morphogenesis and lung-specific cell differentiation (reviewed by Hilfer, 1996) . Mesenchyme recombination studies have demonstrated that lung epithelial morphogenesis is altered, depending on the source of the inducing mesenchyme (Alescio and Cassini, 1962; Shannon, 1994) . Secreted instructive signaling molecules such as transforming growth factor-b (TGF-b) family peptides regulate cell growth, differentiation and tissue morphogenesis through autocrine/ paracrine signaling mechanisms. TGF-b induces growth arrest in various cell types, including lung epithelial cells, and expression of a wide array of proteins, some of which are deposited in the lung extracellular matrix.
Members of the TGF-b superfamily signal through a family of serine/threonine kinase receptors. TGF-b ligands function through a hetero-tetramer cell-surface receptor complex, which consists of two type II and two type I receptors (Massagué et al., 1990; Roberts et al., 1990) . The TGF-b type I/type II receptor complex transphosphorylates intracellular Smad proteins and so results in the propagation of a phosphorylation signal into the nucleus (Wrana et al., 1994; Derynck and Zhang, 1996; Lagna et al., 1996; Heldin et al., 1997) . Over-expression of a cytoplasmically-truncated kinase-domain-deleted TGF-b type II receptor inhibits endogenous TGF-b signaling in a dominant-negative manner, most probably by competing with the endogenous wild-type TGF-b type II receptor for complex formation.
Although TGF-b is known to negatively regulate lung development, the issue of whether the principle function of TGF-b signaling resides in the epithelium or in the mesenchyme remains unresolved. In the current study, we used a novel strategy to introduce exogenous genes to lung epithelium in culture. Intra-tracheal micro-injection of a recombinant adenovirus resulted in epithelium-specific over-expression of a cytoplasmically-truncated, functionally inactive TGF-b type II receptor. Adenovirus-mediated blockade of the TGF-b pathway-signaling in lung epithelial cells stimulated lung epithelial branching morphogenesis while inhibiting the response to exogenous addition of all three mammalian TGF-b peptides and potentiating the stimulatory response to EGF (epidermal growth factor) and PDGF (platelet-derived growth factor). These results provide the first direct evidence that lung epithelium-specific endogenous TGF-b signaling is sufficient to negatively regulate embryonic lung morphogenesis.
Results

Intra-tracheal micro-injection of AdIIR-DN stimulated embryonic lung-branching morphogenesis
AdIIR-DN virus expressing a truncated TGF-b type II receptor was examined for its effect on embryonic lung branching. The truncated TGF-b type II receptor used herein had the cytoplasmic serine/threonine kinase domain deleted, while retaining its capability to bind extracellular TGF-b ligands onto cell surface membranes, thus acting in a dominant-negative fashion (Fig. 1) .
AdIIR-DN virus over-expressing the dominant-negative form of TGF-b type II receptor was micro-injected intratracheally into the primitive airways of E11.5 lung explants, as described in Section 4. Following micro-injection, the E11.5 lungs were cultured for 4 days in chemically-defined, serum-free medium to allow branching morphogenesis to occur. As shown in Fig. 2A(a-d) , enhanced branching morphogenesis was observed in lungs micro-injected with AdIIR-DN virus prior to culture, while unchanged branching was seen in lungs injected with the same titer of control virus (3.0 × 10 10 pfu/ml) in comparison with control media. Stimulation of branching morphogenesis, as determined by quantification of terminal branches, was dependent on AdIIR-DN virus titer (Fig. 2B) . Intra-tracheal micro-injection of 3.0 × 10 9 and 3.0 × l0 10 pfu/ml AdIIR-DN virus stimulated lung-branching by 48 and 65% (P Ͻ 0.05), respectively, while control virus micro-injected at the same titer did not affect lung branching.
To confirm that TGF-b signaling was indeed abrogated by introduction of dominant-negative TGF-b type II receptor, embryonic lungs micro-injected with AdIIR-DN virus versus control virus were treated with exogenous TGF-b ligands. As reported previously, exogenous TGF-bs added to the culture medium were able to decrease lung-branching morphogenesis in ex vivo culture (Serra et al., 1994; Zhao et al., 1996) . However, in the presence of adenovirus-mediated dominant-negative TGF-b type II-receptor over expression, exogenous TGF-bs no longer showed any inhibitory effect on lung branching (Fig. 2C) . Thus, the AdIIR-DN-mediated stimulatory effect on lung branching could not be reversed by addition of TGF-bs, see Fig. 2A (e,f). However, TGF-b1, 2 and 3 all inhibited lung-branching morphogenesis in a dose-dependent fashion when control virus was used. TGF-b2 had the most potent, TGF-b1 had the next, and TGF-b3 had the least potent inhibitory effect on lungbranching morphogenesis see Fig. 2C (a-c).
Adenovirus-mediated over-expression of human truncated TGF-b type II receptor in cultured murine lung
Cultured lungs micro-injected with AdIIR-DN or control virus were extracted for total RNA. Reverse-transcribed products were then subjected to PCR amplification. Only lungs micro-injected with AdIIR-DN, not control virus, expressed the exogenous human dominant-negative TGFb type II receptor gene (Fig. 4A) , when human-specific PCR primers to the N-terminal region of TGF-b type II receptor cDNA were used (shown as arrows 'a' and 'b' in Fig. 1) . To quantify the level of transgene over-expression, a set of primers common to both human and murine TGF-b type II receptor were designed to recognize identical sequences in their respective extracellular domains (Fig. 1, arrows 'c' and 'd') . Competitive PCR methodology was developed to measure the total (exogenous plus endogenous) mRNA amount of TGF-b type II receptor present in micro-injected lungs (Fig. 3) . As shown in Fig. 4A , intratracheal micro-injection of AdIIR-DN resulted in a pfudependent induction of TGF-b type II receptor gene overexpression, while control virus micro-injection at corresponding pfu titers yielded basal levels of endogenous TGF-b type II receptor mRNA. This induction was not observed when PCR primers specific for the intracellular kinase domain of human TGF-b type II receptor was used instead (data not shown), indicating that the outcome of AdIIR-DN infection was over-expression of a dominantnegative form, not wild-type TGF-b type II receptor. Additionally, over-expression of the truncated TGF-b type II receptor transgene did not affect levels of endogenous wild-type murine TGF-b type II receptor gene expression in comparison with media and virus controls (Fig. 4A) , as measured by competitive PCR using a gene-specific primer set to amplify the kinase domain of mouse TGF-b type II receptor cDNA (Fig. 1 , arrows 'e' and 'f'). Thus, intra-tracheal microinjection of AdIIR-DN virus induced pfu titerdependent over-expression of the exogenous truncated mutant TGF-b type II receptor, but not of the endogenous wild-type TGF-b type II receptor gene. A 28-and a 53-fold induction of dominant-negative TGF-b type II receptor gene expression were observed, respectively, when embryonic lungs were micro-injected with AdIIR-DN virus at 3.0 × 10 9 and 3.0 × 10 10 pfu/ml, while infection with control virus failed to show any elevated levels of transgene expression (Fig. 4B) . Consequently, the level of overexpression of dominant-negative mutant TGF-b type II receptor was sufficient to abrogate the endogenous TGF-b pathway during embryonic lung development. The above stimulatory effect could not be reversed by addition of exogenous TGF-b1 ligand (e), while TGFb1 inhibited lung branching when control virus replaced AdIIR-DN for intra-tracheal micro-injection (f). Magnification: 25×. (B) Micro-injection intra-tracheally of AdIIR-DN upregulates lung-branching morphogenesis in a concentration-dependent manner, as determined by the number of terminal branches, while control virus micro-injection did not change lung branching. (C) Addition of TGF-b1, 2 or 3 to the embryonic lung culture could not overcome the stimulatory effect on branching morphogenesis in lungs intra-tracheally micro-injected with AdIIR-DN virus expressing a truncated TGF-b type II receptor, while a dose-dependent inhibition on lung branching was observed in the presence of TGF-b1, 2, or 3 when control virus was used instead for micro-injection.
Intra-tracheal micro-injection of recombinant adenovirus resulted in lung epithelium-specific, but not mesenchymal expression of transgene
To localize the infected cells following recombinant adenovirus micro-injection, AdLacZ virus expressing b-galactosidase was used to trace cells with transgene expression. Cultured embryonic lungs micro-injected intra-tracheally with AdLacZ virus were incubated in X-gal substrate solution to allow blue staining to develop. As shown in the whole-mount in Fig. 5A(a) , airway epithelium, including both proximal and distal sacs, were strongly blue color-stained, while airway epithelium in lungs microinjected with control virus was free of staining (b). In sectioned lung tissues following LacZ color development, see , while both lungs with control virus micro-injection and media control lungs failed to express transgene. A pfu-dependent induction of TGF-b type II receptor mRNA expression was obtained in lungs microinjected with AdIIR-DN when PCR primers specific to both human (exogenous) and murine (endogenous) TGF-b type II receptor were used (also shown as bar graph in (B) after densitometric scanning and calculation by extrapolating from TGF-b type II receptor standard curve (Fig. 3) ), while control virus micro-injection yielded only basal levels of TGF-b type II receptor expression. However, endogenous murine TGF-b type II receptor expression levels remained unchanged regardless of AdIIR-DN or control virus micro-injection, when murine-specific PCR primers to the kinase domain of TGF-b type II receptor was used. exo, exogenous; end, endogenous; 1, 3 × 10 10 pfu/ml AdIIR-DN; 1/10, 3 × l0 9 pfu/ml AdIIR-DN: 1/ 100, 3 × 10 8 pfu/ml AdIIR-DN; VC, virus control.
To localize cells with transgene expression in lungs infected intra-tracheally with AdIIR-DN virus, immunohistochemistry was performed on lung sections using an antibody developed against the N-terminal region of human TGF-b type II receptor (epitope shown as bar 'g' in Fig.  1 ). Exogenous human TGF-b type II receptor protein was detected in both proximal and distal airway epithelial cells with high intensities of staining, while no staining was found in mesenchymal cells, see Fig. 5B (a,b,c1,c2). Immunoactivities in both major and terminal bronchial cells suggested that recombinant adenovirus injected into the tracheal lumen was able to reach the whole respiratory tract (as confirmed by b-galactosidase staining), achieving efficient transfection in epithelial cells lining both proximal and distal airways. In terminal branches, exogenous human TGF-b type II receptor proteins were found to concentrate on the mesenchymal side of the epithelium, adjacent to the basement membrane, see Fig. 5B(c1,c2) , indicating that TGF-b signaling through TGF-b type II receptors may participate in endoderm-mesoderm interaction during embryonic lung development. However, the latter immunocytochemical pattern was no longer obtained when human TGF-b type II receptor C-terminal antibody was used instead of N-terminal antibody (data not shown), further supporting the claim that only the dominant-negative mutant, not wild-type human TGF-b type II receptor protein was present in lung epithelium when AdIIR-DN was used. Lungs micro-injected with control virus only yielded background staining, see Fig. 5B(d) . The endogenous murine TGF-b type II receptor protein expression pattern was not altered, regardless of either AdIIR-DN or control virus infection, as revealed by using mouse-specific antibody to the C-terminal of TGF-b type II receptor (data not shown).
Embryonic lungs intra-tracheally micro-injected with either AdIIR-DN or control virus were mechanically separated into epithelium and mesenchyme upon harvest of culture. Lung epithelium or mesenchyme were separately extracted for total RNA, subjected to reverse transcription, and PCR or competitive PCR. Using PCR primers specific to both human (exogenous) and murine (endogenous) TGFb type II receptor cDNA, TGF-b type II receptor gene, overexpression was only seen in the epithelium of lungs transfected with AdIIR-DN, while TGF-b type II receptor geneexpression levels remained the same in lung mesenchyme, regardless of intra-tracheal viral infection (Fig. 5C ). Exogenous gene expression was only detected in lung epithelium with AdIIR-DN micro-injection, when human TGF-b type II receptor-specific primers were used in PCR amplification. Exogenous gene expression was not observed in lung mesenchyme regardless of whether AdIIR-DN or control virus was used for intra-tracheal micro-injection. Thus, intra-tracheal micro-injection of only AdIIR-DN virus, not control virus, resulted in over-expression of exogenous transgene at both mRNA and protein levels only in airway epithelium, not mesenchyme.
Signaling by other growth factors such as EGF and PDGF was potentiated in lungs infected with AdIIR-DN
Whether infection with AdIIR-DN into lung epithelium may affect signaling mediated by other growth factors was examined. Both EGF and PDGF are known to stimulate embryonic lung epithelial branching morphogenesis when added exogenously into lung culture medium (Warburton et al., 1992; Souza et al., 1995) . Branching morphogenesis in response to either EGF or PDGF-AA was therefore measured in cultured embryonic lungs that had been microinjected with AdIIR-DN virus. As shown in Fig. 6 , both 5 ng/ml EGF and 20 ng/ml PDGF-AA increased lung branching significantly (P Ͼ 0.05). However, in the presence of truncated TGF-b type II receptor over-expression in respiratory epithelium, the stimulatory effects of EC 50 concentrations (concentration at 50% of maximal stimulation) of both EGF and PDGF-AA were potentiated by an additional 33% and 31% respectively (P Ͻ 0.05).
AdIIR-DN transfection into lung epithelium reversed the TGF-b1-induced downregulation of SP-C mRNA level
Surfactant protein C (SP-C) expression was used to evaluate the consequences of epithelium-specific over-expression of AdIIR-DN virus. Exogenously-added TGF-b1 (10 ng/ml) reduced both epithelial branching and epithelial SP-C gene expression in either media control or lungs microinjected with control virus, as measured by competitive PCR quantification of lung SP-C mRNA levels (Fig. 7A) . However, exogenous TGF-b1 no longer inhibited epithelial SP-C mRNA expression when the dominant-negative mutant TGF-b type II receptor was over-expressed in the lung epithelium, indicating that abrogation of TGF-b signaling overcame the downregulation of the SP-C gene by exogenous TGF-b1.
PCNA immunostaining in lung epithelium was increased by AdIIR-DN transfection
Proliferating cell nuclear antigen (PCNA), a 36-kD nuclear protein that is a cofactor for polymerase delta during replication of DNA (Tan et al., 1986; Prelich et al., 1987) , was used as a marker of proliferation rate. In control embryonic lungs treated with 10 ng/ml exogenous TGFb1, PCNA staining, as indicated by the PCNA index (percentage of PCNA-positive cells in airway epithelium) was reduced to 20.8 (P Ͻ 0.05), in comparison with 34.5 in controls without exogenous TGF-b1 (Fig. 7B) . In contrast, the PCNA index in epithelial cells increased to 73.5 (P Ͻ 0.05) in lungs with epithelial over-expression of the truncated TGF-b type II receptor. The PCNA index remained similar (67.9) in AdIIR-DN-transfected lungs in the presence of 10 ng/ml TGF-b1. Thus, addition of exogenous TGF-b1 could not over-ride the increased PCNA staining induced by epithelial transfection of AdIIR-DN. However, PCNA immunoactivity was not changed in lung mesenchymal cells regardless of recombinant adenovirus transfection (data not shown), indicating that micro-injection of AdIIR-DN virus only resulted in cell cycle release in airway epithelial cells.
Discussion
In the present study, a recombinant adenovirus-mediated approach was used to efficiently achieve lung epitheliumspecific over-expression of a dominant-negative TGF-b type II receptor, resulting in blockade of the endogenous epithelial TGF-b pathway and a morphogenetic phenotype of enhanced branching morphogenesis in lung culture. Moreover, TGF-b signaling blockade potentiated responses to other growth factors (EGF and PDGF) on lung-branching morphogenesis.
Much attention has been paid to the development of vectors that can serve to carry genes into cells without themselves affecting normal cellular function. One of the most prominent vectors in use at the present time is the replication-deficient adenovirus. This vector offers many advantages: the virus has a broad host-range, including both replicating and quiescent cells and can therefore infect many different types of cell, the efficiency of exogenous gene delivery and subsequent expression can be extremely high, the virus does not normally integrate into the host genome, and it has minimal adverse effects on intrinsic host-cell function. Therefore, replication-defective adenovirus-mediated gene delivery has been extensively used to introduce functional DNA into somatic cells during organogenesis, resulting in alteration of gene expression in the recipient tissue (reviewed in Baldwin et al., 1997) . Most recently, studies have focused on the utility of adenovirusmediated gene transduction for in utero gene therapy during prenatal development and adenoviral vectors have been used as a method of gene transfer into embryonic stem cells (Sekhon and Larson, 1995; Walter et al., 1996) .
To investigate the role of the endogenous TGF-b pathway during embryonic lung development, we utilized an ex vivo lung explant culture system in which extensive branching morphogenesis occurs in chemically-defined, serum-free medium. A recombinant replication-deficient adenovirus expressing a dominant-negative form of TGF-b type II receptor was devised to achieve transgene expression over 2 ). (C) Using RT-PCR and competitive RT-PCR, human TGF-b type II receptor mRNA was only detected in lung epithelium, not mesenchyme, in lungs micro-injected with AdIIR-DN. Over-expression of exogenous TGF-b type II receptor mRNA relative to its endogenous counterpart was only seen in lung epithelium with AdIIR-DN injection, while pulmonary mesenchyme was not positive for transgene over-expression regardless of AdIIR-DN or control virus injection. E, epithelium; M, mesenchyme. a transient but functionally-significant period of time. In the present study, we have shown that intra-tracheal microinjection of recombinant adenoviruses expressing either marker gene b-galactosidase or the truncated inactive TGF-b type II receptor resulted in infection and transgene mRNA and protein expression only in epithelial cells for at least 4 days. This demonstrated the feasibility of a novel strategy of recombinant adenovirus administration, which resulted in cell type-specific infection and subsequent transgene expression only into lung epithelium in embryonic lung explants.
Delivery of recombinant cytokines is limited by their relatively rapid-clearance half-lives, the necessity of repeated administration, and the problem of TGF-b isoform specificity. Transgenic animal models have overcome some of these problems, and have provided useful insights into the role of TGF-b signaling. Lung tissue-specific promoters such as the Clara cell-specific CC-10 promoter and the surfactant protein C promoter direct over-expression to alveolar type II cells, resulting in models of TGF-b overexpression (Korfhagen et al., 1994; Zhou et al., 1996) . However, these transgenic models introduce early and prolonged transgene expression, resulting in distortions of normal physiology. We therefore utilized a transient but efficient transgene approach using a replication-defective recombinant adenovirus to over-express the inactive mutant TGF-b type II receptor into lung epithelium. Herein, we demonstrated that successful delivery of the transgene resulted in persistent transgene expression during the 4-day culture period during which the embryonic lung-branching pattern develops in culture.
A truncated, cytoplasmic kinase domain-deleted human TGF-b type II receptor was used in the current study. The mutant TGF-b type II receptor is incapable of signaling, while retaining the ability to bind to and sequester extracellular TGF-b ligands on the cell surface. Truncated TGF-b type II receptors have been used successfully to block TGFb signaling both in cells in culture and in transgenic mice (Yamamoto et al., 1996; Böttinger et al., 1997; Serra et al., 1997) . Our data showed a 53-fold excess of mutated TGF-b type II receptor gene expression in cultured lungs infected with recombinant adenovirus, in comparison with cultured lungs without transgene. This level of expression of dominant-negative receptor was sufficient to abrogate both the endogenous TGF-b pathway and the effect of exogenous TGF-bs. However, while respiratory epithelial cells were efficiently transfected, mesenchymal cells were not affected by intra-tracheal micro-injection of recombinant adenovirus. Thus, blockade of TGF-b signaling in epithelium alone was sufficient to stimulate embryonic lung branching morphogenesis in culture. Therefore, endogenous TGF-b signaling in primitive lung epithelium is sufficient to negatively regulate embryonic lung branching morphogenesis. The observed stimulation of branching morphogenesis in cultured lungs with respiratory epithelium-specific dominant-negative TGF-b type II receptor transgene introduction is attributed to the release of TGF-b-induced inhibition of airway epithelial cell growth.
TGF-b has been shown not only to regulate lung epithelial branching morphogenesis, but also to affect mesenchy- Fig. 7 . Blockade of TGF-b1-mediated downregulation of SP-C gene expression (A) and PCNA immunoactivity (B) in lungs with AdIIR-DN micro-injection. TGF-b1, when exogenously added, reduced SP-C mRNA expression in lung epithelium. However, in lungs with epithelial overexpression of a dominant-negative TGF-b type II receptor, SP-C mRNA level was not decreased by exogenous TGF-b1 ligand. While epithelial PCNA staining was decreased by addition of exogenous TGF-b1 in control lung culture, introduction of ADIIR-DN into lung epithelium increased PCNA immunostaining relative to control. This upregulation of epithelial PCNA staining by AdIIR-DN micro-injection was not reversed by exogenous TGF-b1. mal cell proliferation in culture (Lee et al., 1997) . TGF-b peptides regulate extracellular matrix protein synthesis, including type I, III and IV collagens, elastin, fibronectin and tenascin (Zhou et al., 1993; Maniscalco et al., 1994; Kawamoto et al., 1995; Zhao and Young, 1995) . As an alternative to intra-tracheal micro-injection, embryonic lung explants were submerged in adenovirus-containing medium for 1 h prior to culture. AdLacZ-submerged lungs were stained cytochemically for b-gal protein expression after culture, and demonstrated b-gal staining exclusively in the pleural cells and most external mesenchymal cells, while bronchial epithelial cells were negative for b-gal staining (Zhao et al., unpublished data) . Using recombinant adenovirus in a similar manner, we over-expressed a mutated active TGF-b1 ligand in the pleura and peripheral pulmonary mesenchyme, which resulted in induction of matrix protein gene expression including fibronectin and matrix Gla protein, while both epithelial branching morphogenesis and cytodifferentiation were not affected. Our data therefore suggest that TGF-b signaling acts locally in a highly spatially-restricted manner, to regulate epithelial branching morphogenesis and cytodifferentiation as well as matrix gene expression. Recombinant adenovirusmediated gene transfer has also been shown to achieve an efficient transgene expression in primarily embryonic lung mesenchymal cell culture (unpublished data), indicating that adenoviral gene transfer functions in both organ and cell culture systems.
Intra-tracheal administration of recombinant adenovirus has been shown to result in infection and transgene mRNA and protein expression in the epithelial cells of small and respiratory bronchioles as well as adjacent alveoli in adult animals (Xing et al., 1994; Sime et al., 1997) . However, mesenchymal cells are usually free of transgene expression despite intra-tracheal transfection. Our preliminary results have demonstrated that both mesenchymal cells in lung explant culture and primary embryonic mesenchymal cells in culture, over-express exogenous genes following adenovirus-mediated gene transduction, indicating that embryonic lung epithelial and mesenchymal cells can be efficiently transfected with replication-deficient recombinant adenovirus. While the mechanism by which intra-tracheallymediated adenoviral gene delivery is limited to the pulmonary epithelium is currently unknown, we speculate that the lack of exogenous gene transduction in pulmonary mesenchyme following intra-tracheal micro-injection is due to the limited permeability of recombinant adenovirus in lung explants. Pulmonary epithelium may form a steric barrier to prevent mesenchymal cells from acquiring adenoviral transfection upon intra-tracheal administration.
Introduction of the dominant-negative mutant TGF-b type II receptor also prevented the TGF-b-mediated downregulation of SP-C gene expression, indicating that endogenous TGF-bs no longer exert negative effects on SP-C gene regulation. Since the cellular composition (epithelial vs. mesenchymal cells) were not significantly altered after either exogenous TGF-b ligand addition or over-expression of adenovirus-mediated transgene through intra-tracheal micro-injection (data not shown), the reduction of SP-C by exogenous TGF-b1 over-expression cannot be a function of a ratio change of epithelial cells to mesenchymal cells, but rather the TGF-b-induced downregulation on surfactant proteins. The current study therefore provides direct evidence that surfactant protein gene expression is regulated by modulation of TGF-b signaling in lung epithelium. Increased PCNA immunoreactivity was also observed in lung epithelial cells transfected with truncated mutant TGF-b type II receptor, indicating that TGF-b-mediated cell growth arrest at late G1 phase was released by blockade of endogenous TGF-b signaling. While TGF-b alone induced decreased PCNA immunoactivity in lung epithelium, it is conceivable that stimulation of epithelial lung development in the presence of truncated TGF-b type II receptor over-expression is attributable to the efficient abrogation of endogenous TGF-b signaling in lung epithelium.
In summary, using a recombinant adenoviral vector combined with intra-tracheal microinjection enables efficient gene transfer and robust expression of the transferred gene in primitive respiratory epithelium. Using this approach, we have shown that (i) an excess of the truncated TGF-b type II receptor was expressed specifically in lung epithelium, without affecting the mRNA levels of endogenous wildtype TGF-b type II receptor (Fig. 4) and (ii) expression of the truncated TGF-b type II receptor completely and specifically abolished both the negative proliferative effect and SP-C gene expression effect of endogenous TGF-b signaling. The data presented herein strongly support the notion that endogenous TGF-b signaling in lung epithelium imposes negative regulation on airway epithelial cell growth, epithelial branching morphogenesis and epithelialspecific gene expression, since all of these effects were reversed by epithelium-specific transfer of a dominantnegative TGF-b type II receptor. We speculate that endogenous TGF-b signaling through the type II receptor may serve to negatively regulate lung epithelial branching by inhibiting positive signaling by other cognate peptide growth factor receptor pathways including EGFR, PDGFR and FGFR (Warburton et al., 1992; Miettinen et al., 1995; Miettinen et al., 1997; Souza et al., 1995; Bonström et al., 1996) . Certainly, the dominant-negative TGF-b type II receptor potentiated the stimulatory responses to EC 50 concentration of FGF and PDGF-AA.
Materials and methods
Recombinant adenoviruses
A replication-deficient recombinant adenovirus expressing a dominant-negative TGF-b type II receptor was constructed as described previously (Yamamoto et al., 1996) . Briefly, a human TGF-b type II receptor cDNA, with its cytoplasmic kinase domain deleted, was cloned into a shuttle vector containing a CA promoter comprising a cytomegalovirus enhancer and a chicken b-actin promoter (Niwa et al., 1991 ). The recombinant adenovirus was then generated by homologous recombination in 293 cells using shuttle vector and a virus-rescuing vector (Graham and Prevec, 1990) . The resultant recombinant adenovirus, designated as AdIIR-DN, was expanded and purified by ultracentrifugation through a CsCl gradient followed by dialysis (Xing et al., 1996) . The titer of the virus was determined by a plaque formation assay using 293 cells and expressed as plaque formation unit (pfu). The control virus containing no exogenous gene was also used. AdLacZ expressing b-galactosidase was prepared to localize transgene in transfected cells (Sime et al., 1997) .
Intra-tracheal micro-injection
Pregnant Swiss-Webster mice were sacrificed on postcoitum day 11.5 (E11.5) and the embryos were removed. Lung primordia with attached tracheae were isolated from embryos in Hank's medium by micro-dissection under sterile conditions as we previously described (Warburton et al., 1992) . Microinjection of recombinant adenovirus was performed using a PV830 Pneumatic Picopump (World Precision Instruments, Sarasota, FL). Recombinant adenovirus diluted to desirable concentrations (in PBS) was loaded into micro-injection needles (inner and outer gauge 100 and 200 mm, respectively). Micro-injection was performed, under a microscope, by carefully inserting the virus-filled needle into the tracheal lumen. Three to five pulses of 20 nl virus-containing solution were then micro-injected intra-tracheally into the embryonic respiratory tract, until both proximal and distal airways of the lung explants were filled with injected adenovirus. Injected lungs were incubated for 1 h at room temperature for viral transfection prior to lung culture.
Embryonic lung culture
Following virus administration, E11.5 lung explants were cultured under serum-free, chemically-defined conditions for 4 days, as reported previously (Jaskoll et al., 1988; Zhao et al., 1996) . TGF-b1, 2, 3, EGF or PDGF-AA ligands (R&D Systems, Minneapolis, MN) were added exogenously to culture medium at known concentrations. Cultured lungs were saved for either histological examination or competitive RT-PCR measurement for mRNA amounts of genes of interest.
Quantification of branching morphogenesis
Since branching morphogenesis per se is the key bioassay read-out of the biological effects of TGF-b signaling in the current study, we devised three independent measurements of branching morphogenesis: (i) the number of airway generations from the trachea to the most distal branch of the longest visible airway, (ii) the number of air sacs visible around the periphery of the lung explants and (iii) computerized pattern recognition analysis of the number of individual terminal respiratory units in the whole explant. These analyses were performed on wholemounts of lung explants, using trans-illumination to visualize structures, and photomicroscopy to record permanent image, and on paraffinembedded sections of fixed tissue.
RNA extraction and reverse transcription
Total RNA from each individually-cultured lung explant was extracted for total RNA using guanidinium thiocyanate following homogenization utilizing Total RNA Isolation Kit from 5′prime-3′prime (West Chester, PA). Extracted total RNA was immediately reverse transcribed as documented elsewhere (Zhao et al., 1998) . The resultant cDNA products were used for competitive PCR assay.
Competitive PCR
Development of competitive PCR methodology for mRNA quantification of pulmonary genes has been described elsewhere Zhao and Warburton, 1997) . Briefly, a set of primers (primers A and B, Fig.  3A) were designed for human TGF-b type II receptor to amplify a cDNA fragment of 372 bp in size (Lin et al., 1992) . Two composite primers were synthesized for TGFb type II receptor competitor construction (Fig. 3A) : each composite primer had the target TGF-b type II receptor primer sequence (black box) incorporated into a stretch of sequence (hatched box) designed to hybridize to the opposite strand of heterologous DNA fragment. The desired primer sequences (primers A and B) were thus engineered into a competitor cDNA using PCR amplification, ensuring that both TGF-b type II receptor cDNA and its competitor utilized the same set of primers in TGF-b type II receptor competitive PCR. The TGF-b type II receptor competitor was 480 bp in length. Both TGF-b type II cDNA and its competitor were DNA sequenced to confirm their identities (Sanger et al., 1977) .
PCR amplification was carried out in a Robocycler (Stratagene, La Jolla, CA) using a modification of a previouslydescribed assay for matrix Gla protein . Thirty-five cycles of denaturation at 94°C for 1 min, annealing at 60°C for 2 min and extension at 72°C for 2 min were routinely performed after an initial 3-min denaturation at 94°C. The final cycle included a 5-min extension step. The reaction mixture contained 10 mM Tris-HCl (pH 9.4), 50 mM KCl, 2 mM MgCl 2 (optimized), 0.01% gelatin, 0.1% Triton X-100, 20 pmol primer sets, 100 pM dNTP and 0.5 unit Advantage Klentech DNA polymerase (Clontech, Palo Alto, CA). Reaction mixture containing a known amount of competitor was added to reverse-transcribed samples derived from 20 ng total RNA or to dilutions of standard cDNA templates in a total volume of 50 ml. The concentration of cDNA standard solutions were determined spectrophotometrically on absorbance at 260 nm using 1 A 260 = 50 mg/ml. b-Actin competitive PCR as an internal control was performed on the same samples. As a negative control for genomic DNA or adenoviral DNA, non-reversetranscribed total RNA and adenoviral DNA were also included in the competitive PCR assays.
Cytochemical staining
Cultured embryonic lungs micro-injected with AdLacZ virus were fixed in 2% formaldehyde containing 0.2% glutaraldehyde for 1 h and transferred into a substrate solution containing 0.5 mg/ml X-gal. Color development was processed at 37°C for 1 h to generate blue staining, and was terminated when optimal staining was achieved. The whole lungs were photographed under microscope using trans-illuminant light. Lungs were subsequently plastic-embedded using a JB-4 kit (Polysciences, Warrington, PA) and sectioned (5 mm thick). Sections were counterstained with 0.1% nuclear fast red, examined histologically and photographed for permanent records. Lung explants transfected with control virus or untransfected lungs were processed together with those infected with AdLacZ to yield negative controls.
Immunocytochemistry and morphometry
Cultured lung explants were fixed with paraformaldehyde upon harvest and embedded into paraffin. Embryonic lung sections (5 mm thick) on HistoGrip-coated slides were prepared for immunohistochemical study. TGF-b type II receptor N-terminal antibody (rabbit polyclonal IgG, Upstate Biotech., Lake Placid, NY) was used at a concentration of 10 mg/ml for TGF-b type II receptor protein immunostaining. Biotinylated second antibody and streptavidin-peroxidase conjugate were used to detect bound antibody. Subsequent addition of aminoethyl carbazole chromogen (AEC) generated a reddish precipitate surrounding the TGF-b type II receptor antigen (Zymed, San Francisco, CA). Three negative controls were run in parallel with TGF-b type II receptor antibody to ensure specificity: (1) polyclonal IgG pre-absorbed with blocking peptide, (2) bovine serum albumin and (3) water control.
PCNA immunostaining was performed in a similar manner as for TGF-b type II receptor, using a polyclonal IgG antibody at a final concentration of 5 mg/ml (Dako, Carpinteria, CA). Sections were subsequently counterstained with hematoxylin. Morphometric analysis was carried out according to the methods we previously described (Zhao et al., 1996) . Lung sections were examined by light microscopy at high magnification. All epithelial and mesenchymal cell nuclei in each selected field were scored blind as either PCNA-positive (red from AEC staining) or PCNAnegative (blue from hematoxylin). More than 1000 cells were scored for each specimen and at least ten specimens were evaluated for each assayed condition. The PCNA index (percentage of PCNA-positive nuclei) for each specimen was calculated as red nuclei/(red nuclei + blue nuclei) × 100 and its mean value represented an average from at least ten individual lung sections in each condition.
Densitometric and statistical analysis
DNA electrophoresis following PCR amplification was performed on 3% agarose gels (3:1 mixture of Nusieve and Seakem, FMC, Rockland, ME) in a submarine gel unit (CBS Scientific, Del Mar, CA), where target and competitor PCR products were separated by size. Gels were stained with 5 mg/ml ethidium bromide. Images were both photographed by Polaroid 667 films for permanent record and captured by a computer for intensity measurement. The intensity was determined by densitometric analysis in pixels using ImageQuan band-analyzing software (Molecular Dynamics, Sunnyvale, CA). Calculation and statistical analysis were performed using Microsoft Excel 5.0.
Every experiment was repeated at least three times, with reproducible results. Standard deviation (SD) was derived from 5 or 6 individual lung explants for each assayed condition. P Ͻ 0.05 (evaluated by t-test) was accepted as statistically significant.
